Navigation Links
Unigene Announces Positive Top-Line Results of Phase 2 Oral PTH Study for the Treatment of Osteoporosis in Postmenopausal Women
Date:11/9/2011

ry endpoints evaluated biochemical markers of bone formation and resorption, as well as the safety, tolerability and pharmacokinetics of the oral formulation.

About Unigene-GSK Exclusive Worldwide Licensing Agreement

On December 10, 2010, Unigene entered into an amended and restated exclusive worldwide license agreement with GSK to develop and commercialize an oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women. Under the terms of the amended and restated agreement, Unigene was responsible for the manufacture of the PTH and the conduct of the Phase 2 study. To date, the Company received a total of $8 million in relation to the Phase 2 study.  Unigene is eligible to receive further payments of up to approximately $140 million based on the achievement of regulatory and commercialization milestones. In addition, Unigene is eligible to receive tiered double-digit royalties in the low-to-mid teens on global sales. Based on a review of the Phase 2 data, GSK may elect to assume responsibility for all future development and commercialization of the product.

Unigene will formally submit the Phase 2 Clinical Study Report to GSK by the end of the year.  GSK has up to 75 days following submission of the report to inform Unigene whether it will proceed with the clinical development of the oral formulation of a recombinantly produced PTH analog for the treatment of osteoporosis in postmenopausal women pursuant to the terms of the exclusive worldwide licensing agreement.

About Osteoporosis

Osteoporosis is a disease in which bones become brittle and so are more likely to break. In osteoporotic women and men, the density and quality of bone are reduced, leading to deterioration of the skeleton and increased risk of fracture. It's often diagnosed only after an osteoporosis-related fracture happens because prior to such an event, the patient has no outward signs or
'/>"/>

SOURCE Unigene Laboratories, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Tarsa Therapeutics and Unigene Present Preclinical Data Suggesting Calcitonin May Have Utility in Combination Therapy for the Treatment of Osteoarthritis
2. China-Biotics, Inc. Announces Conference Call to Discuss First Quarter 2009 Financial Results
3. Odyssey Thera Announces Milestone Achievement in Pfizer Alliance
4. InNexus Biotechnology Announces Launch of Large Scale Primate Study of DXL625
5. Anesiva Announces Second Quarter 2008 Financial Results and Update
6. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
7. Insmed Announces Financial Results for Second Quarter and Six-Months Ended June 30, 2008
8. China Sky One Medical, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
9. China Yingxia International, Inc. Announces Conference Call to Discuss Second Quarter 2008 Results
10. ThirdBiotech Announces Kemeta as Newest Sponsor
11. Signalife Announces Intent to Withdraw From AMEX and Trade on the OTCBB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... August 19, 2014 Sales Horizons, a ... its online sales skills training course to ... , MedTech clinical staff spend the majority of their ... standalone medical center, or physician practice – providing support ... why stop there? Sales Horizons believes clinical staff are ...
(Date:8/18/2014)... FREDERICK, Md. , Aug. 18, 2014 ... the maker of advanced consumer medical devices ... Kotak was interviewed by CEOLIVE.TV as ... The entire interview is available at ... interview Dr. Kotak explains to investors the ...
(Date:8/18/2014)... 18, 2014 According to ... Research "Life Science Reagents Market(Products- PCR Reagent Kits, ... In-Vitro Diagnostic Reagents and Others; End Users- Commercial ... Laboratories, and Forensic Laboratories)- Global Industry Analysis, Size, ... the global life science reagents market was valued ...
(Date:8/18/2014)... China is increasingly being recognized ... research industry. Clinicaltrial.gov statistics highlight the popularity of ... population; a high increase in infectious diseases; a ... pool of patients and a track record of ... China also presents challenges for the clinical research ...
Breaking Biology Technology:Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 2Sales Horizons Launches a New Online Sales Training Course for MedTech Clinical Staff to Develop Their Sales Skills 3BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 2BioElectronics EVP Dr. Deepak Kotak Interviewed on CEO Live 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 2Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 3Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 4Global Life Science Reagents Market Expected to Reach USD 25.7 Billion in 2019: Transparency Market Research 5China – Land of Opportunities & Challenges for the Clinical Research Industry, New Webinar Hosted by Xtalks 2
... March 20 On Wednesday, April 29, 2009, Wyeth (NYSE: ... 2009 first quarter. The Company will hold a forty-five minute ... on April 29, 2009. Interested investors and others may ... through our Internet webcast, which may be accessed by visiting ...
... Solos Endoscopy, Inc. (Pink Sheets: SNDY) is pleased ... agreement with Lifeline Biotechnologies, Inc. (Pink Sheets: LLBO) ... to Lifeline Biotechnologies for a combination of stock, ... Endoscopy originally purchased the products from Lifeline Biotechnologies ...
... has shown that certain marginalized groups including the ... African Americans and Latinos fare worse than others ... injuries and fatalities. , Now, a ... that they also experience greater terrorism-related fears and make ...
Cached Biology Technology:Wyeth Sets Webcast and Conference Call for 2009 First Quarter Earnings 2Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc. 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
(Date:8/19/2014)... It,s not a monkey. It,s not a lemur. It,s ... Meet the Philippine tarsier: a tiny, adorable and downright "cool" ... animals that Americans are familiar with," said Rafe Brown, curator-in-charge ... giant eyes and ears; an extremely cute, furry body; a ... interesting expanded fingers and toe tips that look a bit ...
(Date:8/19/2014)... a new implantable tissue scaffold coated with bone growth ... When applied to bone injuries or defects, this coated ... that looks and behaves just like the original tissue. ... dramatic improvement over the current standard for treating bone ... the patient,s body a painful process that does ...
(Date:8/19/2014)... ( Aug. 19, 2014 ) -- Scientists at the ... pick up and transfer single cells using a pipette ... They describe this engineering feat and preliminary test results ... the American Chemical Society . , "Studying single cells ... current biomedical research," said nanomedicine department. faculty member Lidong ...
Breaking Biology News(10 mins):Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 2Philippine tarsier gets boost from Kansas research, and genetic proof of a new variety 3Engineering new bone growth 2Engineering new bone growth 3Moving single cells around -- accurately and cheaply 2
... NY-- A multinational team of scientists has identified a single gene, ... fruit and seeds of the oil palm are the source of ... provide one of the most promising sources of biofuel. ... high-quality full genome map of the oil palm plant and to ...
... in California,s Central Valley, one of the world,s most ... species miles from farmland. Writing in Environmental Toxicology ... Tree Fogs in remote mountain areas, including national parks; ... by the elements. California,s Central Valley is one ...
... The following statement is being issued by Robbins Geller Rudman & Dowd ... Litigation SUPERIOR COURT OF THE STATE OF CALIFORNIA ... IN RE PACIFIC BIOSCIENCES OF CALIFORNIA , INC. SECURITIES ... OF PROPOSED SETTLEMENT OF CLASS ACTION Hon. Marie S. Weiner ...
Cached Biology News:Full genome map of oil palm indicates a way to raise yields and protect rainforest 2Full genome map of oil palm indicates a way to raise yields and protect rainforest 3Pesticides contaminate frogs from Californian National Parks 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 2Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 3Robbins Geller Rudman & Dowd LLP and Scott+Scott, Attorneys at Law, LLP Announce Proposed Settlement of Class Action in the Pacific Biosciences Securities Litigation 4
Negative Control, eluted and packaged aseptically in 20l of 10mM Tris-HCL, pH 8.0, 1 mM EDTA, 5 years at either 4°C or -20°C...
AdestaTM Tissue/Cell Preservation Medium Sterile / Non-sterile: Sterility Tested Endotoxin: ...
...
... Clone/PAD: ZMD.440. Immunogen: Synthetic peptide derived ... PDGF-D (platelet derived growth factor D iris-expressed ... which differs from mouse and rat by ... with the ~50 kDa human mouse and ...
Biology Products: